Drug intelligence / Profile preview

Melaxin

Development stage: Discontinued
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Melaxin is an autologous cellular vaccine developed for the treatment of malignant melanoma. It functions as an immunotherapy by creating "dendritomas," which are hybrid fusion cells formed by combining a patient's own tumor cells with their dendritic cells. These dendritomas are designed to present the full repertoire of tumor antigens to the immune system, thereby stimulating an anti-tumor immune response. In clinical trials, Melaxin has been investigated for its efficacy in Stage IV malignant melanoma, administered subcutaneously in combination with Bacillus Calmette-Guerin (BCG) injections.

Beyond the preview

Go deeper on Melaxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melaxin.

Explore the full profile